Clinical And Plantar Fascial Morphologic Changes After Proximal Medial Gastrocnemius Release Treatment of Recalcitrant Plantar Fasciitis

• Main Authors: Alberto Ginés-Cespedosa MD, PhD, Ignacio Wormull Ugarte MD, Jesus Ares-Vidal MD, Alberto Solano-Lopez MD, Daniel Bianco Adames MD, Carlo Gamba MD
• Format: Article
• Language: English
• Published: SAGE Publishing 2021-07-01
• Series: Foot & Ankle Orthopaedics
• Online Access: https://doi.org/10.1177/24730114211027323

Background: Magnetic resonance imaging (MRI) has been used as a diagnostic and prognostic instrument to evaluate the results of conservative treatment for plantar fasciitis. However, there are scarce data available relative to changes in the plantar fascia after operative treatment. The primary objective of this study is to evaluate the imaging changes in patients with recalcitrant plantar fasciitis treated operatively by means of proximal medial gastrocnemius release. Methods: Thirteen patients with recalcitrant plantar fasciitis were studied with MRI preoperatively and 1 year after operative treatment. Quantitative (plantar fascia thickness) and qualitative variables (hyperintensity in the plantar fascia, insertional calcaneus bone edema, a plantar fascia tear, and the presence of perifascial collections) were assessed by 2 musculoskeletal radiologists. Clinical results were also measured with American Orthopaedic Ankle & Society (AOFAS), visual analog scale (VAS) pain, and 36-Item Short Form Health Survey (SF-36) scales. Results: The mean plantar fascia thickness was 6.59 mm preoperatively and 6.37 mm postoperatively ( P = .972). No statistically significant differences were found in any of the qualitative variables on comparing the pre- and postoperative periods. Patients reported clinical improvements in pain VAS, AOFAS measurement, and the physical subdomains of the SF-36 scale. Conclusion: Quantitative and qualitative variables assessed for the plantar fascia on MRI did not show any significant change after medial gastrocnemius release despite clear clinical improvement. Level of Evidence: Level II, perspective cohort study.